These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 17683362

  • 1. Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura.
    Moore JC, Arnold DM, Leber BF, Clare R, Molnar GJ, Kelton JG.
    Vox Sang; 2007 Aug; 93(2):173-5. PubMed ID: 17683362
    [Abstract] [Full Text] [Related]

  • 2. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
    Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ.
    Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
    [Abstract] [Full Text] [Related]

  • 3. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.
    Cataland SR, Jin M, Ferketich AK, Kennedy MS, Kraut EH, George JN, Wu HM.
    Br J Haematol; 2007 Jan; 136(1):146-9. PubMed ID: 17069579
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity.
    Cataland SR, Jin M, Lin S, Kennedy MS, Kraut EH, George JN, Wu HM.
    Br J Haematol; 2007 Nov; 139(3):486-93. PubMed ID: 17910638
    [Abstract] [Full Text] [Related]

  • 5. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
    Coppo P, Veyradier A.
    Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
    [Abstract] [Full Text] [Related]

  • 6. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
    Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M.
    J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
    [Abstract] [Full Text] [Related]

  • 7. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
    Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, Scalzulli PR, Paolini R, Marcenò R, Remuzzi G, Galbusera M.
    Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
    [Abstract] [Full Text] [Related]

  • 8. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.
    Cataland SR, Jin M, Lin S, Kraut EH, George JN, Wu HM.
    Am J Hematol; 2008 Dec; 83(12):911-5. PubMed ID: 18821711
    [Abstract] [Full Text] [Related]

  • 9. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C, Schiviz A, De Meyer SF, Plaimauer B, Scheiflinger F, Rottensteiner H, Vanhoorelbeke K.
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011.
    Kawano N, Yokota-Ikeda N, Yoshida S, Kuriyama T, Yamashita K, Sugio Y, Makino S, Ono N, Inoue Y, Himeji D, Kodama K, Uezono S, Shimao Y, Ueda A, Matsumoto M, Iino H, Fujimura Y.
    Intern Med; 2013 Nov; 52(17):1883-91. PubMed ID: 23994977
    [Abstract] [Full Text] [Related]

  • 13. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.
    Patriquin CJ, Thomas MR, Dutt T, McGuckin S, Blombery PA, Cranfield T, Westwood JP, Scully M.
    Br J Haematol; 2016 Jun; 173(5):779-85. PubMed ID: 27009919
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura.
    O'Brien KL, Price TH, Howell C, Delaney M.
    J Clin Apher; 2013 Dec; 28(6):416-21. PubMed ID: 23857424
    [Abstract] [Full Text] [Related]

  • 17. Current insight into thrombotic thrombocytopenic purpura.
    Verbeke L, Delforge M, Dierickx D.
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
    Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld JP.
    Blood; 2005 Sep 15; 106(6):1932-7. PubMed ID: 15933059
    [Abstract] [Full Text] [Related]

  • 20. Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange.
    Chai W, Chaudhry A, Rabinowitz AP.
    J Clin Apher; 2015 Feb 15; 30(1):46-9. PubMed ID: 24782109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.